After a tough first year as CEO, Merck's (MRK +1%) Ken Frazier expects a better 2012, pointing...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

After a tough first year as CEO, Merck's (MRK +1%) Ken Frazier expects a better 2012, pointing to key new drugs on the horizon and pursuing deals for others in late testing. But that shift could hint at trouble, one observer notes: "Looking for late-stage deals is not a sign of confidence in the internal late-stage pipeline. Nothing is more expensive than a late-stage deal."